Study of Patient Features, Treatment Approaches, and Outcomes for Surgically Removed Lung Cancers in China

What this Trial Is About

This research aims to understand characteristics, treatment patterns, and outcomes for patients in China who have had lung cancers surgically removed. It focuses on how treatments and patient features have changed over time, especially with advances like minimally invasive surgery, targeted therapy, and immunotherapy. The study also seeks to identify factors linked to overall survival and address new clinical questions related to early-stage lung cancer care. The study observes patients diagnosed with lung cancer who have undergone surgical resection at participating medical centers. It collects real-world data from January 2014 through December 2031, including treatment approaches and pathological details. An analytic framework is used to process and ensure the quality of data, supporting the evaluation of survival outcomes and evolving treatment trends. Participants contribute clinical data that is carefully reviewed and analyzed over several years. Researchers will assess baseline characteristics, treatment patterns, and pathological features up to December 2028, with ongoing monitoring of overall survival until the end of 2031. A planned analysis will occur between April and August 2024, with final results expected in 2032. This long-term observational study helps track real-world outcomes in lung cancer patients after surgery.

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers